Share price of this pharmaceutical company moved up by nearly 4.90 percent to Rs. 425.20 in the morning trading session of Monday, compared to its previous close of Rs. 405.35, after its subsidiary won an order.
With a market capitalisation of Rs. 683.26 crore, at 11:16 a.m. the share price of Kilitch Drugs (India) Ltd. was trading in the green at Rs. 423.6, up by 4.50 percent.
The company has delivered positive returns of nearly 126.71 percent in the last six months, and over 195.4 percent in the last one year. So far in 2024, it has given positive returns of around 15.68 percent.
According to the stock exchange filings, the subsidiary of Kilitch Drugs (India) Limited, Kilitch Estro Biotech PLC, has won an order issued for the supply of Pharmaceuticals.
The order is issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia and the price of the contract is approximately Rs. 75.69 crores.
In terms of financials, the revenue from operations of the company reduced by 22.83 percent QoQ from Rs. 41.20 crore in Q2 FY23-24 to Rs. 31.79 crore in Q3 FY23-24.
The company’s net profit also decreased by nearly 65.81 percent to Rs. 1.74 crore in Q3 FY23-24 from Rs. 5.09 crore in Q2 FY22-23.
As of December 2023, the Promoters’ holdings remain unchanged at 69.23 percent, whereas the Public holdings decreased by 0.02 percent from 30.78 percent in Q2 FY23-24 to 30.76 percent in Q3 FY23-24.
Founded in 1978, Kilitch Drugs is a pharmaceutical company, and its services range from manufacturing to marketing a host of formulations in all dosage forms.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
